Off-color performances for a number of innovative medicines took the shine off Novartis AG’s third quarter although the Swiss firm did enjoy a strong launch trajectory for Pluvicto and positive top-line data for potential pipeline-in-a-pill iptacopan as it prepares for its new chapter as a pure-play pharma firm.
Weak Spots Blight Novartis Third Quarter As New Products Shine
A mixed sales bag for the Swiss major in Q3 saw a strong start for Pluvicto dampened by a reverse for Zolgensma, weak growth for Cosentyx and continued sluggishness for Leqvio. Positive data for potential blockbuster iptacopan were another bright spot, as Novartis prioritizes the delivery of high value medicines, and concentrates on the US market.
